Given that thrombotic risk is significantly affected by race, researchers suggested that these findings may indicate that pulmonary vasculopathy may contribute to the unexplained differences in racial susceptibility to COVID-19 mortality.
This data analysis suggested that larotrectinib is highly effective in patients with NTRK gene fusions, however offered minimal benefit in patients with other non-fusion NTRK alterations.
A recent clinical trial’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer.
The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab.
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.
Researchers analyzed pooled data from 159 patients enrolled in 3 larotrectinib trials to assess outcomes stratified by prior lines of therapy and ECOG performance status.
The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.
The breast cancer expert discussed the implications of this approval, as well as the data that led to the approval of sacituzumab govitecan-hziy.
The American Society of Clinical Oncology and its affiliate organization the Association for Clinical Oncology announced the results of a survey that focused on the changes in cancer care due to COVID-19.
The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available.
Updated interim results from the phase Ib/II CLASSICAL-Lung study showed promise for pepinemab in combination with avelumab in patients with advanced stage non-small cell lung cancer.
A recent study examined pancreatic metastases to understand why patients with this particular kidney cancer have better prognoses, and sought to characterize the clinical behavior, therapeutic implications, and underlying biology of this type of cancer.
Encouraging interim data were reported from the ongoing phase I clinical trial of STRO-002 regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer.
New clinical trial practices specific to cancer include new risk assessment strategies, decentralized and remote trial coordination, data collection, and delegation of specific therapeutic activities.